37 results
8-K
EX-10.1
KA
Kineta Inc
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating
8-K
EX-10.1
KA
Kineta Inc
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating
8-K
EX-99.6
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate
425
lj6xdf34nzy7qdci
6 Jun 22
Business combination disclosure
4:05pm
8-K
EX-2.6
6imeu2ii1n7
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-2.2
xirdhhtyw0tbxeh
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-10.1
ldjveblixz04h961o
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
6mijk6 jc
16 Jun 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
lxj74q3fm
17 May 21
Regulation FD Disclosure
5:03pm
8-K
EX-1.1
nb0z98ck9
8 Apr 21
Entry into a Material Definitive Agreement
9:06am
8-K/A
EX-99.3
i1eyamgohsedriv
3 Feb 21
Other Events
4:59pm
8-K
EX-99.1
f2n4e9jn
11 Jan 21
Regulation FD Disclosure
6:30am
8-K
EX-10.1
mwj2ni09moth7nds
15 Dec 20
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis
7:34am